Hanna B Christensen1, David E Gloriam2, Daniel Sejer Pedersen3, Jack B Cowland4, Niels Borregaard5, Hans Bräuner-Osborne6. 1. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark. Electronic address: hania.belcik@gmail.com. 2. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark. Electronic address: david.gloriam@sund.ku.dk. 3. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark. Electronic address: daniel.pedersen@sund.ku.dk. 4. Granulocyte Research Laboratory, Department of Hematology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. Electronic address: Jack.Cowland@regionh.dk. 5. Granulocyte Research Laboratory, Department of Hematology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. 6. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark. Electronic address: hbo@sund.ku.dk.
Abstract
INTRODUCTION: The label-free dynamic mass redistribution-based assay (DMR) is a powerful method for studying signalling pathways of G protein-coupled receptors (GPCRs). Herein we present the label-free DMR assay as a robust readout for pharmacological characterization of formyl peptide receptors (FPRs) in human neutrophils. METHODS: Neutrophils were isolated from fresh human blood and their responses to FPR1 and FPR2 agonists, i.e. compound 43, fMLF and WKYMVm were measured in a label-free DMR assay using Epic Benchtop System from Corning®. Obtained DMR traces were used to calculate agonist potencies. RESULTS: The potencies (pEC50) of fMLF, WKYMVm and compound 43, determined on human neutrophils using the label-free DMR assay were 8.63, 7.76 and 5.92, respectively. The DMR response to fMLF, but not WKYMVm and compound 43 could be blocked by the FPR1-specific antagonist cyclosporin H. DISCUSSION: We conclude that the DMR assay can be used, and complements more traditional methods, to study the signalling and pharmacology of endogenous FPR receptors in human neutrophils.
INTRODUCTION: The label-free dynamic mass redistribution-based assay (DMR) is a powerful method for studying signalling pathways of G protein-coupled receptors (GPCRs). Herein we present the label-free DMR assay as a robust readout for pharmacological characterization of formyl peptide receptors (FPRs) in human neutrophils. METHODS: Neutrophils were isolated from fresh human blood and their responses to FPR1 and FPR2 agonists, i.e. compound 43, fMLF and WKYMVm were measured in a label-free DMR assay using Epic Benchtop System from Corning®. Obtained DMR traces were used to calculate agonist potencies. RESULTS: The potencies (pEC50) of fMLF, WKYMVm and compound 43, determined on human neutrophils using the label-free DMR assay were 8.63, 7.76 and 5.92, respectively. The DMR response to fMLF, but not WKYMVm and compound 43 could be blocked by the FPR1-specific antagonist cyclosporin H. DISCUSSION: We conclude that the DMR assay can be used, and complements more traditional methods, to study the signalling and pharmacology of endogenous FPR receptors in human neutrophils.
Authors: Michael W Boesgaard; Kasper Harpsøe; Michelle Malmberg; Christina R Underwood; Asuka Inoue; Jesper M Mathiesen; Gabriele M König; Evi Kostenis; David E Gloriam; Hans Bräuner-Osborne Journal: J Biol Chem Date: 2020-08-04 Impact factor: 5.157
Authors: C Ämmälä; W J Drury; L Knerr; I Ahlstedt; P Stillemark-Billton; C Wennberg-Huldt; E-M Andersson; E Valeur; R Jansson-Löfmark; D Janzén; L Sundström; J Meuller; J Claesson; P Andersson; C Johansson; R G Lee; T P Prakash; P P Seth; B P Monia; S Andersson Journal: Sci Adv Date: 2018-10-17 Impact factor: 14.136